Medtronic Plc (MDT) Stock Price & Analysis

Medtronic Plc (MDT) rose 1.15% to USD 94.17 as of September 8, 2026 at 02:51 UTC, according to Nexqual real-time market data.

MDT last closed at USD 94.17; the session ranged USD 92.31–94.74 on volume of 8,627,339 shares. Market capitalization is —, with a 52-week range of USD 73.31–106.33 (NYQ). Source: Nexqual, September 8, 2026 at 02:51 UTC.

Key Statistics (as of September 8, 2026 at 02:51 UTC)

Technical Analysis (MDT)

Nexqual's technical model rates MDT "STRONG BUY" based on 5 bullish and 0 bearish signals across 128 daily candles, as of September 8, 2026 at 02:51 UTC.

From Medtronic Plc's Latest SEC 10-K Filing (filed 2026-06-18)

Key Strengths & Strategy (as disclosed to the SEC)

• FDA and other regulatory bodies, both in and outside the U.S. (including the Federal Trade Commission, the Office of the Inspector General of the Department of Health and Human Services (HSS), the U.S.
• Our NURO System delivers Percutaneous Tibial Neuromodulation therapy to treat overactive bladder, (non-obtrusive) urinary retention, including the Altaviva system, and chronic fecal incontinence.
• Intellectual Property and Litigation We rely on a combination of patents, trademarks, tradenames, copyrights, trade secrets, and agreements, including non-disclosure agreements, to protect our business and proprietary technology.
• Development by other companies of new or improved products, processes, technologies, or the introduction of reprocessed products or competitive devices when our proprietary products lose their patent protection may make our existing or planned products less competitive.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 02:51 UTC. This page is informational and not investment advice.